Floatz logo

SEVELAMER

Obesity and Glomerulopathy

Zhi-Hong Liu, M.D.OtherN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Obesity and Glomerulopathy cohort.

Asset / SponsorPhaseRating
Irbesartan
Zhi-Hong Liu, M.D.
N/AD

Same molecule, other indications

SEVELAMER is also rated in:

kidney disorderDormant
B
Indicative ·
59 / 100
View asset →
chronic kidney diseaseDormant
B
Indicative ·
59 / 100
View asset →
end stage renal failureDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →